Insider Selling: Amicus Therapeutics, Inc. (NASDAQ:FOLD) Insider Sells $451,500.00 in Stock

Amicus Therapeutics, Inc. (NASDAQ:FOLD) insider Jay Barth sold 30,000 shares of the stock in a transaction dated Monday, July 27th. The stock was sold at an average price of $15.05, for a total transaction of $451,500.00. Following the sale, the insider now owns 193,204 shares of the company’s stock, valued at approximately $2,907,720.20. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Jay Barth also recently made the following trade(s):

  • On Thursday, July 9th, Jay Barth sold 44,447 shares of Amicus Therapeutics stock. The stock was sold at an average price of $15.92, for a total transaction of $707,596.24.
  • On Tuesday, July 7th, Jay Barth sold 178,988 shares of Amicus Therapeutics stock. The stock was sold at an average price of $15.90, for a total transaction of $2,845,909.20.
  • On Monday, June 29th, Jay Barth sold 30,000 shares of Amicus Therapeutics stock. The stock was sold at an average price of $15.51, for a total transaction of $465,300.00.
  • On Wednesday, June 17th, Jay Barth sold 1,904 shares of Amicus Therapeutics stock. The shares were sold at an average price of $13.47, for a total transaction of $25,646.88.

Shares of NASDAQ FOLD opened at $14.45 on Friday. The firm has a market capitalization of $3.78 billion, a PE ratio of -11.12 and a beta of 1.35. The company has a current ratio of 4.45, a quick ratio of 4.31 and a debt-to-equity ratio of 0.50. Amicus Therapeutics, Inc. has a 1 year low of $6.25 and a 1 year high of $16.13. The firm’s 50-day moving average is $14.69 and its 200-day moving average is $11.58.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.07). Amicus Therapeutics had a negative return on equity of 63.24% and a negative net margin of 155.73%. The firm had revenue of $60.53 million for the quarter, compared to the consensus estimate of $57.21 million. As a group, equities research analysts anticipate that Amicus Therapeutics, Inc. will post -1.08 earnings per share for the current fiscal year.

A number of institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. boosted its stake in Amicus Therapeutics by 1.8% during the 1st quarter. BlackRock Inc. now owns 21,239,016 shares of the biopharmaceutical company’s stock worth $196,248,000 after acquiring an additional 382,909 shares during the last quarter. Janus Henderson Group PLC lifted its position in Amicus Therapeutics by 8.1% during the first quarter. Janus Henderson Group PLC now owns 11,625,924 shares of the biopharmaceutical company’s stock worth $107,423,000 after purchasing an additional 867,308 shares during the period. State Street Corp lifted its position in Amicus Therapeutics by 1.2% during the first quarter. State Street Corp now owns 11,129,151 shares of the biopharmaceutical company’s stock worth $102,833,000 after purchasing an additional 132,427 shares during the period. Nuveen Asset Management LLC lifted its position in Amicus Therapeutics by 92.8% during the fourth quarter. Nuveen Asset Management LLC now owns 4,154,771 shares of the biopharmaceutical company’s stock worth $40,468,000 after purchasing an additional 2,000,176 shares during the period. Finally, Deutsche Bank AG lifted its position in Amicus Therapeutics by 153.1% during the first quarter. Deutsche Bank AG now owns 4,121,255 shares of the biopharmaceutical company’s stock worth $38,080,000 after purchasing an additional 2,492,623 shares during the period.

FOLD has been the subject of several research reports. JPMorgan Chase & Co. restated a “buy” rating on shares of Amicus Therapeutics in a research report on Monday, June 8th. SVB Leerink restated a “market perform” rating and issued a $19.00 price objective on shares of Amicus Therapeutics in a research report on Tuesday, May 19th. BidaskClub upgraded shares of Amicus Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, June 30th. BTIG Research initiated coverage on shares of Amicus Therapeutics in a research report on Tuesday, June 16th. They issued a “buy” rating and a $19.00 price objective for the company. Finally, Zacks Investment Research cut shares of Amicus Therapeutics from a “hold” rating to a “sell” rating and set a $16.00 price objective for the company. in a research report on Wednesday, July 22nd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the stock. Amicus Therapeutics has an average rating of “Buy” and a consensus price target of $19.83.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease.

Recommended Story: Put Option

Insider Buying and Selling by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.